Matthew R Sarkisian
Overview
Explore the profile of Matthew R Sarkisian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1732
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Silver A, Chakraborty A, Pittu A, Feier D, Anica M, West I, et al.
Comput Struct Biotechnol J
. 2024 Dec;
23:4337-4349.
PMID: 39697680
Analyzing the local microenvironment of tumor cells can provide significant insights into their complex interactions with their cellular surroundings, including immune cells. By quantifying the prevalence and distances of certain...
2.
Silver A, Chakraborty A, Pittu A, Feier D, Anica M, West I, et al.
bioRxiv
. 2024 Aug;
PMID: 39149345
Motivation: Analyzing the local microenvironment of tumor cells can provide significant insights into their complex interactions with their cellular surroundings, including immune cells. By quantifying the prevalence and distances of...
3.
Chakraborty A, Yang C, Kresak J, Silver A, Feier D, Tian G, et al.
Cells
. 2024 Jun;
13(11.
PMID: 38891070
Glioblastoma (GBM) poses a significant challenge in clinical oncology due to its aggressive nature, heterogeneity, and resistance to therapies. Cancer stem cells (CSCs) play a critical role in GBM, particularly...
4.
Tian J, Mallinger J, Shi P, Ling D, Deleyrolle L, Lin M, et al.
Transl Oncol
. 2024 Apr;
45:101956.
PMID: 38640786
Tumor Treating Fields (TTFields) extend the survival of glioblastoma (GBM) patients by interfering with a broad range of tumor cellular processes. Among these, TTFields disrupt primary cilia stability on GBM...
5.
Deleyrolle L, Sarkisian M
Dev Neurosci
. 2024 Apr;
45(3):139-146.
PMID: 38630257
Glioblastoma (GBM), the most common and lethal primary brain tumor in adults, requires multi-treatment intervention which unfortunately barely shifts the needle in overall survival. The treatment options after diagnosis and...
6.
Chakraborty A, Yang C, Kresak J, Silver A, Feier D, Tian G, et al.
bioRxiv
. 2024 Mar;
PMID: 38501121
Glioblastoma (GBM) poses a significant challenge in clinical oncology due to its aggressive nature, heterogeneity, and resistance to therapies. Cancer stem cells (CSCs) play a critical role in GBM, particularly...
7.
Shi P, Tian J, Mallinger J, Ling D, Deleyrolle L, McIntyre J, et al.
Cells
. 2023 Oct;
12(19).
PMID: 37830570
ADP-ribosylation factor-like protein 13B (ARL13B), a regulatory GTPase and guanine exchange factor (GEF), enriches in primary cilia and promotes tumorigenesis in part by regulating Smoothened (SMO), GLI, and Sonic Hedgehog...
8.
Lee D, Gimple R, Wu X, Prager B, Qiu Z, Wu Q, et al.
J Clin Invest
. 2022 Nov;
133(2).
PMID: 36394953
Glioblastoma ranks among the most aggressive and lethal of all human cancers. Self-renewing, highly tumorigenic glioblastoma stem cells (GSCs) contribute to therapeutic resistance and maintain cellular heterogeneity. Here, we interrogated...
9.
Silver A, Feier D, Ghosh T, Rahman M, Huang J, Sarkisian M, et al.
Front Oncol
. 2022 Nov;
12:1022716.
PMID: 36338705
Glioblastoma (GBM) is an extremely aggressive and incurable primary brain tumor with a 10-year survival of just 0.71%. Cancer stem cells (CSCs) are thought to seed GBM's inevitable recurrence by...
10.
Shi P, Tian J, Ulm B, Mallinger J, Khoshbouei H, Deleyrolle L, et al.
Front Oncol
. 2022 Apr;
12:837589.
PMID: 35359402
Tumor Treating Fields (TTFields) are low-intensity, alternating intermediate-frequency (200 kHz) electrical fields that extend survival of glioblastoma patients receiving maintenance temozolomide (TMZ) chemotherapy. How TTFields exert efficacy on cancer over...